Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV001509329 | SCV001715978 | likely pathogenic | not provided | 2020-01-08 | criteria provided, single submitter | clinical testing | PVS1, PM2 |
Gene |
RCV001509329 | SCV001778760 | pathogenic | not provided | 2024-03-16 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 37805811) |
Labcorp Genetics |
RCV001859355 | SCV002229926 | pathogenic | Cortical dysplasia-focal epilepsy syndrome | 2022-12-08 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs771533907, gnomAD 0.003%). This sequence change creates a premature translational stop signal (p.Arg1095*) in the CNTNAP2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CNTNAP2 are known to be pathogenic (PMID: 19896112, 21827697, 25045150, 26843181, 27439707). This variant has not been reported in the literature in individuals affected with CNTNAP2-related conditions. For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 1163876). |